HS GovTech Solutions Inc.
HDSLF · Other OTC · USD
0,386USD
−0,0015 (−0,39 %)Stand 15. Nov., 19:26
Kennzahlen
- Eröffnung
- 0,3875
- Vortag
- 0,3875
- Tagesspanne
- 0,386 – 0,3875
- 52 Wochen
- 0,135 – 0,45
- Volumen
- 42.570
- Ø Volumen
- 47.245
- Börsenwert
- 21,13 Mio. $
- KGV
- -3,2
- Gewinn je Aktie (TTM)
- -0,12
- Dividendenrendite
- 0,0 %
- Beta
- -0,6
- Nächste Zahlen
- –
Finanzen
| USD | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Umsatz | 6,03 Mio. | 5,68 Mio. | 2,65 Mio. | 2,59 Mio. | 2,2 Mio. |
| Herstellungskosten | 1,54 Mio. | 1,58 Mio. | 873.389 | 0 | 0 |
| Bruttogewinn | 4,49 Mio. | 4,1 Mio. | 1,77 Mio. | 2,59 Mio. | 2,2 Mio. |
| Forschung und Entwicklung | 55.875 | 59.509 | 275.819 | 0 | 0 |
| Vertrieb und Verwaltung | 8,99 Mio. | 8,54 Mio. | 3,06 Mio. | 3 Mio. | 2,86 Mio. |
| Operatives Ergebnis | −5,18 Mio. | −4,98 Mio. | −1,82 Mio. | −632.345 | −848.981 |
| EBITDA | −4,32 Mio. | −4,29 Mio. | −1,3 Mio. | −408.541 | −631.808 |
| Nettogewinn | −5,29 Mio. | −4,99 Mio. | −1,83 Mio. | −753.397 | −943.026 |
| Gewinn je Aktie (verwässert) | -0,12 | -0,14 | -0,09 | -0,04 | -0,06 |
Bewertung
Letzte 12 Monate
- KGV
- -3,2
- Kurs-Umsatz-Verhältnis
- 3,5
- Kurs-Buchwert-Verhältnis
- 5,1
- PEG
- 0,1
- Bruttomarge
- 74,4 %
- Operative Marge
- −86,0 %
- Nettomarge
- −87,8 %
- Verschuldungsgrad
- 0,4
- EV/EBITDA
- -5,1
- Eigenkapitalrendite
- −131,3 %
- Kapitalrendite (ROIC)
- −106,4 %
- Free-Cashflow-Rendite
- −24,9 %
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Bruttomarge | 74,4 % | 72,2 % | 67,0 % | 100,0 % | 100,0 % |
| Operative Marge | −86,0 % | −87,6 % | −68,9 % | −24,5 % | −38,6 % |
| Nettomarge | −87,8 % | −87,9 % | −69,2 % | −29,1 % | −42,9 % |
| KGV | -2,2 | -4,0 | -5,2 | -6,0 | -3,9 |
| Kurs-Umsatz-Verhältnis | 1,9 | 3,6 | 3,6 | 1,7 | 1,7 |
| Kurs-Buchwert-Verhältnis | 3,4 | 4,4 | 3,7 | 2,5 | 1,6 |
| Verschuldungsgrad | 0,4 | 0,0 | 0,3 | 0,4 | 0,2 |
| Liquidität 3. Grades | 0,6 | 1,0 | 0,7 | 0,5 | 0,5 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 12,5 Mio. | 19,57 Mio. | 9,37 Mio. | 5,13 Mio. | 3,78 Mio. |
| EV/EBITDA | -2,9 | -4,6 | -7,2 | -12,5 | -6,0 |
| Eigenkapitalrendite | −155,2 % | −107,3 % | −71,7 % | −42,2 % | −41,4 % |
| Kapitalrendite (ROIC) | −106,4 % | −103,5 % | −54,7 % | −24,6 % | −30,9 % |
| Free-Cashflow-Rendite | −44,9 % | −22,5 % | −14,1 % | −5,7 % | −38,5 % |
Wachstum
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Umsatz | +6,2 % | +114,4 % | +2,4 % | +17,6 % | +15,0 % |
| Bruttogewinn | +9,4 % | +131,0 % | −31,4 % | +17,6 % | +15,0 % |
| Operatives Ergebnis | −4,2 % | −172,9 % | −188,4 % | +25,5 % | +45,5 % |
| Nettogewinn | −6,0 % | −172,2 % | −143,3 % | +20,1 % | +48,2 % |
| Gewinn je Aktie | +14,3 % | −52,2 % | −115,0 % | +30,5 % | +63,8 % |
| Freier Cashflow | −14,0 % | −241,2 % | −424,6 % | +81,8 % | −42,2 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Mai 2023 | Dez. 2022 | Nov. 2022 | Aug. 2022 | Mai 2022 | Dez. 2021 | Nov. 2021 | Juli 2021 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | -0,02 | -0,03 | -0,04 | -0,02 | -0,02 | -0,03 | -0,01 | -0,07 |
| Abweichung | – | – | – | – | – | – | – | – |
| Umsatz · Tatsächlich | 1,89 Mio. | 6,03 Mio. | 1,23 Mio. | 1,83 Mio. | 1,5 Mio. | 5,68 Mio. | 1,89 Mio. | 955.735 |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 4. Dez. 20201:8
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
ATHJFAntisense Therapeutics Limited0,012−76,00 %
GRAMFTPCO Holding Corp.0,1587−15,36 %
KBBTFKubota Pharmaceutical Holdings Co., Ltd.0,960,00 %
KMSTFKadimastem Ltd3,21−3,02 %
OCELOrganicell Regenerative Medicine, Inc.2,7425−0,27 %
PCHMPharmChem, Inc.3,75+0,27 %
RTNXFRenalytix Plc0,080,00 %
THKKFThink Research Corporation0,226−1,74 %
Über das Unternehmen
HS GovTech Solutions Inc. operates as a Software-as-a-Service (SaaS) provider, specializing in the development and sale of information and communication management systems. These systems are specifically designed for the health inspection departments of federal, provincial, state, and municipal governments across Canada and the United States. The company offers a comprehensive suite of products. Among them is HSCloud, a low-code data management platform that assists state and local government agencies in efficiently managing applications, licenses, permits, inspections, and other operational data. For field operations, HSTouch provides a robust data collection solution, functioning both online and offline. It allows users to record observations, access calendars, review past inspections, refer to regulatory codes and violations, capture electronic signatures, embed photos, and email inspection reports directly from the field. Further enhancing its offerings, HS GovTech provides EnviroIntel EHS Manager, an internet-based client/server application for filling out forms, requesting information, and viewing real-time reports. Public health agencies benefit from HSTrace, a sophisticated disease surveillance tool that enables them to track new cases during outbreaks and utilize advanced communication and tracking features to stay connected with individuals affected by illness. To streamline financial operations, HSPay is a proprietary payment solution designed to digitize and simplify revenue collection for client agencies. The portfolio also includes GovCall, a platform for teleconferencing and group communication, and MyHealthDepartment.com, a versatile web platform. This portal allows users to apply for services, view and interact with inspection reports and permits, monitor application statuses, and facilitate smoother communication with regulatory bodies. Founded in 1998, the company was initially known as HealthSpace Data Systems Ltd. It adopted its current name, HS GovTech Solutions Inc., in April 2022 and is headquartered in Chilliwack, Canada.
Führung
- Silas GarrisonChief Executive Officer & Director
- Ali HakimzadehExecutive Chairman
- Joseph WillmottPres & Director
- Dean ChristieChief Financial Officer
- Warwick George SmithMember of Advisory Board
- Theo YeungVice President of Sales & Growth
- CEO
- Silas Garrison
- Mitarbeitende
- 91
- Hauptsitz
- Chilliwack, BC, CA
- Sektor
- Healthcare
- Branche
- Medical - Healthcare Information Services
- Börsengang
- 17. Jan. 2018
- Website
- hsgovtech.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.